GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » Shiller PE Ratio

Affymax (Affymax) Shiller PE Ratio : (As of Apr. 28, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Affymax Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Affymax Shiller PE Ratio Historical Data

The historical data trend for Affymax's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax Shiller PE Ratio Chart

Affymax Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Affymax Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Affymax's Shiller PE Ratio

For the Biotechnology subindustry, Affymax's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymax's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Affymax's Shiller PE Ratio falls into.



Affymax Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Affymax's E10 for the quarter that ended in Jun. 2014 is calculated as:

For example, Affymax's adjusted earnings per share data for the three months ended in Jun. 2014 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2014 (Change)*Current CPI (Jun. 2014)
=0.19/100.5595*100.5595
=0.190

Current CPI (Jun. 2014) = 100.5595.

Affymax Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200409 -17.600 80.121 -22.090
200412 -17.600 80.290 -22.043
200503 -23.057 81.555 -28.430
200506 -23.057 82.062 -28.254
200509 -23.057 83.876 -27.643
200512 -32.480 83.032 -39.336
200603 -20.340 84.298 -24.264
200606 -23.490 85.606 -27.593
200609 -4.760 85.606 -5.591
200612 -0.524 85.142 -0.619
200703 -0.480 86.640 -0.557
200706 -0.620 87.906 -0.709
200709 -0.850 87.964 -0.972
200712 -0.920 88.616 -1.044
200803 -1.030 90.090 -1.150
200806 -1.240 92.320 -1.351
200809 -1.720 92.307 -1.874
200812 -1.680 88.697 -1.905
200903 -1.320 89.744 -1.479
200906 -1.170 91.003 -1.293
200909 -0.970 91.120 -1.070
200912 -0.630 91.111 -0.695
201003 -0.330 91.821 -0.361
201006 0.700 91.962 0.765
201009 -0.490 92.162 -0.535
201012 -0.460 92.474 -0.500
201103 -0.360 94.283 -0.384
201106 -0.350 95.235 -0.370
201109 -0.280 95.727 -0.294
201112 -0.860 95.213 -0.908
201203 0.870 96.783 0.904
201206 -0.890 96.819 -0.924
201209 -0.680 97.633 -0.700
201212 -1.850 96.871 -1.920
201303 -0.720 98.209 -0.737
201306 0.410 98.518 0.418
201309 -0.050 98.790 -0.051
201312 -0.040 98.326 -0.041
201403 -0.040 99.695 -0.040
201406 0.190 100.560 0.190

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Affymax  (OTCPK:AFFY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Affymax Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Affymax's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymax (Affymax) Business Description

Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
Executives
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson officer: Chief Financial Officer 8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp officer: Chief Commercial Officer 4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte director
Karin L Walker officer: VP, Finance & CAO C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton director
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland officer: EVP, Corp. Development and CFO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris director, officer: CEO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor 05-13-2010

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor 05-19-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor 09-30-2009